NCT06430697

Brief Summary

Paracetamol is commonly used in case of pain or fever. Few previously clinical studies has highlighted an arterial hypotension linked to intravenous administration of paracetamol. Currently, fewer data are available on the link of intravenous administration of paracetamol and effects on arterial tension. The aim of this study is to describe the frequency of occurrence of significative arterial hypotension within one hour following intravenous or per os administration of paracetamol . Other factors who can be associated to occurence of significative arterial hypotension will be also observe (for example age, weight, pain, vasopressor dosage or sedative...)

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
10mo left

Started Jun 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
Jun 2024Apr 2027

First Submitted

Initial submission to the registry

May 16, 2024

Completed
12 days until next milestone

First Posted

Study publicly available on registry

May 28, 2024

Completed
4 days until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2027

Last Updated

May 29, 2024

Status Verified

May 1, 2024

Enrollment Period

2.5 years

First QC Date

May 16, 2024

Last Update Submit

May 27, 2024

Conditions

Keywords

Intensive Care UnitPARACETAMOLblood pressure

Outcome Measures

Primary Outcomes (1)

  • Measure frequency of low blood pressure following paracetamol administration

    Proportion of patients with clinically significant low blood pressure occurring within one hour of administration of paracetamol IV or per os. Clinically significant low blood pressure is defined as an average blood pressure of less than 60 mmHg and/or a decrease in average blood pressure of more than 15%, and/or need for vascular filling and/or initiation or increase of the dose of noradrenaline

    One hour after administration of paracetamol

Secondary Outcomes (4)

  • Measure of blood pressure following paracetamol administration according to IGS II score

    One hour after administration of paracetamol

  • identify predictors linked to paracetamol administration route

    One hour after administration of paracetamol

  • identify predictors linked to paracetamol dosage

    One hour after administration of paracetamol

  • Measure of blood pressure following paracetamol administration according to SOFA score

    One hour after administration of paracetamol

Study Arms (1)

Treatment with paracetamol

EXPERIMENTAL
Drug: paracetamol administration

Interventions

Patient hospitalized in Intensive Care Unit with a continuous measurement of blood pressure with a catheter and who have an administration of paracetamol by intravenous or per os

Treatment with paracetamol

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Patient with arterial catheter
  • Indication of paracetamol's administration by the patient's attending practitioner.
  • No opposition to patient or support person participation in the study if the patient is unable to participate
  • No Social Security Patient
  • Pregnant or nursing patient.
  • Patient with a legal protection measure
  • Hypersensitivity and/or allergy to paracetamol.
  • Contraindication to the use of paracetamol.
  • Patient opposition to health data collection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de NICE ARCHET

Nice, 06000, France

Location

Central Study Contacts

Kamila BURDZENIDZE, Study nurse

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 16, 2024

First Posted

May 28, 2024

Study Start

June 1, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

April 1, 2027

Last Updated

May 29, 2024

Record last verified: 2024-05

Locations